| scholarly article | Q13442814 |
| P2093 | author name string | Barry S Komm | |
| C Richard Lyttle | |||
| Peter V N Bodine | |||
| Christopher P Miller | |||
| Yogendra Kharode | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| estrogen | Q277954 | ||
| P304 | page(s) | 6084-6091 | |
| P577 | publication date | 2008-08-14 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention | |
| P478 | volume | 149 |
| Q59125691 | A comprehensive overview on osteoporosis and its risk factors |
| Q37352516 | A new approach to menopausal therapy: the tissue selective estrogen complex |
| Q38149162 | Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause |
| Q30455905 | Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention |
| Q37698607 | Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis |
| Q30409045 | Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes |
| Q28066699 | Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy |
| Q92437297 | Conjugated Estrogens and Bazedoxifene Improve β Cell Function in Obese Menopausal Women |
| Q38193873 | Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause |
| Q38192058 | Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy |
| Q33642558 | Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination |
| Q90512364 | Effects of bazedoxifene and low-intensity aerobic exercise on bone and fat parameters in ovariectomized rats |
| Q44620640 | Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women |
| Q43253442 | Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy |
| Q35092811 | Efficacy and safety of bazedoxifene for postmenopausal osteoporosis |
| Q38307019 | Emerging hormonal treatments for menopausal symptoms |
| Q33638802 | Endometrial profile of tamoxifen and low-dose estradiol combination therapy |
| Q37648048 | Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment |
| Q64355560 | Estrogens Promote Misfolded Proinsulin Degradation to Protect Insulin Production and Delay Diabetes |
| Q38077503 | Evolution of the tissue selective estrogen complex (TSEC). |
| Q37444596 | GPER-novel membrane oestrogen receptor |
| Q43715217 | Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. |
| Q44341394 | Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women |
| Q37983700 | Importance of oestrogen receptors to preserve functional β-cell mass in diabetes |
| Q35092609 | Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan |
| Q35885187 | Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy |
| Q26825692 | Nuclear receptors and their selective pharmacologic modulators |
| Q38231326 | Osteoporosis in the at-risk asthmatic |
| Q26751149 | Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene |
| Q38102040 | Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. |
| Q33384192 | Pharmacology and clinical applications of selective estrogen receptor modulators |
| Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
| Q37156496 | Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer |
| Q37808639 | Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE) |
| Q37048294 | Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture |
| Q55070816 | Prostaglandin dependent control of an endogenous estrogen receptor agonist by osteoblasts. |
| Q40344336 | Protective effects of bazedoxifene paired with conjugated estrogens on pancreatic β-cell dysfunction |
| Q56390891 | Recent Developments in Pharmacotherapy for Vasomotor Symptoms |
| Q44278781 | Recommendations on the management of fragility fracture risk in women younger than 70 years |
| Q33866426 | Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy |
| Q37743272 | SERMs and SERMs with estrogen for postmenopausal osteoporosis |
| Q34134828 | Selective estrogen receptor modulators: tissue specificity and clinical utility |
| Q48189748 | The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause. |
| Q35001394 | The conundrum of estrogen receptor oscillatory activity in the search for an appropriate hormone replacement therapy. |
| Q37631061 | The endometrium--from estrogens alone to TSECs |
| Q26827973 | The evolution of selective estrogen receptor modulators in osteoporosis therapy |
| Q38993271 | The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms |
| Q36864744 | The role of estrogens in control of energy balance and glucose homeostasis |
| Q37277298 | The tissue selective estrogen complex: a promising new menopausal therapy |
| Q53837780 | Tissue selective estrogen complex (TSEC): a review. |
| Q30456770 | Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model |
| Q37304372 | Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. |
| Q37801227 | Tissue-Selective Agents: Selective Estrogen Receptor Modulators and the Tissue-Selective Estrogen Complex |
| Q37636428 | Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. |
| Q37768158 | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms |
| Q34271979 | Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review |
| Q35110859 | Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model |
Search more.